The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

A diabetes diet is a healthy eating plan that helps control your blood sugar. Here are the best foods to eat, no matter what type of diabetes you have.

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

Key Takeaways A new ICD-10 diagnosis code, E11.A, now formally recognizes type 2 diabetes in remissionRemission requires an ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Authors say in those without diabetes, continuous glucose monitors are not a substitute for HbA1c. (HealthDay News) — Continuous glucose monitors (CGMs) do not accurately reflect blood sugar control ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials.

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...